Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a MK-6194 in Adult Non-Segmental Vitiligo
2023-503502-37-00Phase 2Completed
- Sponsor
- Merck & Co.
- Start
- Dec 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 18
01
Overview
Phase 2, randomised, double-blind trial in Vitiligo comparing MK-6194 with Placebo to MK-6194 (2 arms). Primary endpoints: Change from Baseline in Facial Vitiligo Area Scoring Index (F-VASI) at Week 24, Number of Participants Who Experience an Adverse Event (AE) and 1 more. Started Dec 2023; status: completed.
02
Drugs
PT101
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2023-503502-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-503502-37-00.